AIDS in Biological Technology

GeoVax Labs, Inc. Provides Clinical Studies Update

... and MVA express the three major proteins of the aids virus: Gag, Pol, and Env, and produce ... mimic more than half of the components of the aids virus, but cannot cause AIDS. This multi-protein ... Virus) and other infectious agents. GeoVax's aids vaccine technology is the subject of 20 issued or ...

GeoVax Labs, Inc. Announces Resignation of Director

... Virus) and other infectious agents. GeoVax's aids vaccine technology is the subject of 20 issued or filed patent applications. GeoVax aids vaccines are designed for use in uninfected ... should the person ever become infected. GeoVax aids vaccines also may be effective as therapeutics ...

GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois

... each year. Globally, there are about 2.5 million aids infections per year, most involving subtypes AG, ... UNAIDS reported 1.3 million people living with aids in North America and 33.2 million people living with aids worldwide. Presently, there is little to prevent ...

New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance

... Faster reporting aids physicians in identifying HIV mutations that can ... an antiretroviral therapy. About HIV and aids HIV, or the human immunodeficiency virus, is ... their function. The two major viruses that cause aids are HIV-1 and HIV-2. The most common, HIV-1, is ...

Prescription-Free Digital Hearing Aid Just Released

... when compared to the price of traditional hearing aids from a doctor's office. While hearing aids can cost between $4,000 and $8,000 from a ... HearPod, Inc. - Hearing Aids: HearPod hearing aids are the successful culmination of 30 years of ...

GeoVax Labs, Inc. Announces First Quarter Financial Results

... are also pleased with our Phase 2a preventative aids human trial commencement of injections in ... Virus) and other infectious agents. GeoVax's aids vaccine technology is the subject of 20 issued or filed patent applications. GeoVax aids vaccines are designed for use in uninfected ...

Mylan's Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments

... quality treatments has helped transform aids from a fatal illness into a manageable chronic ... According to the Joint United Nations Program on aids (UNAIDS), an estimated 33 million people in the ... reduced the average annual cost per patient of aids treatment. I also would like to recognize the ...

GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results

... 2008, GeoVax presented data on its Phase 1 aids vaccine trial (HVTN 065) at the aids Vaccine 2008 conference, in Cape Town, ... data for the full dose of the GeoVax aids vaccine with a view to protecting ...

GeoVax Update Provided at the BIO CEO & Investor Conference 2009

... Virus) and other infectious agents. GeoVax's aids vaccine technology is the subject of 20 issued or filed patent applications. GeoVax aids vaccines are designed for use in uninfected ... should the person ever become infected. GeoVax aids vaccines also may be effective as therapeutics ...

GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference

... of 20 issued or filed patent applications. GeoVax aids vaccines are designed for use in uninfected ... caused by the virus known as HIV-1. GeoVax aids vaccines also may be effective as a ... with the HIV-1 virus. GeoVax's core aids vaccine technologies were developed by Dr. ...

Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS

... fight infections and certain cancers resulting in aids (Acquired Immune Deficiency Syndrome). Individuals diagnosed with aids are susceptible to life-threatening diseases ... now over 33 million people living with HIV and aids worldwide. CCR5 is the chemokine receptor ...

GeoVax to Present at the BIO CEO & Investor Conference 2009

... of 20 issued or filed patent applications. GeoVax aids vaccines are designed for use in uninfected ... should the person ever become infected. GeoVax aids vaccines also may be effective as therapeutics, ... infected with AIDS virus. GeoVax's core aids vaccine technologies were developed by Dr. ...

GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update

... of both components (DNA and MVA) of its aids vaccine to the HIV Vaccine Trials Network ... data for the full dose of the GeoVax aids vaccine. This trial will serve as a major ... 15, 2008, GeoVax presented data on its Phase 1 aids vaccine trial (HVTN 065) at ...

Sangamo BioSciences Presents Data at ICAAC Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic

... the opportunistic infections characteristic of aids as well as the virus itself. We look forward to ... both opportunistic infections characteristic of aids and HIV itself. The modified cells exhibited the ... fight infections and certain cancers resulting in aids (Acquired Immune Deficiency Syndrome). ...

GeoVax's DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial

... it has shipped both DNA and MVA components of its aids vaccine to the HIV Vaccine Trials Network ... its planned Phase 2a trial commencement. GeoVax aids vaccines are designed to prevent development of ... Virus) and other infectious agents. GeoVax's aids vaccine technology is the subject of 20 issued or ...

GeoVax Presents Data at AIDS Vaccine 2008 Conference

... of infectious diseases, presented data on their aids vaccine (trial HVTN 065) at the AIDS Vaccine 2008 ... CEO and President of GeoVax Labs, Inc. "The aids Vaccine 2008 conference is a meeting of the minds ... data for the full dose of the GeoVax aids vaccine. Dr. Harriet Robinson, the developer of ...

GeoVax Labs, Inc. Information To Be Available Through Standard & Poor's Market Access Program

... Virus) and other infectious agents. GeoVax's aids vaccine technology is the subject of 20 issued or filed patent applications. GeoVax aids vaccines are designed for use in uninfected ... should the person ever become infected. GeoVax aids vaccines also may be effective as therapeutics, ...

Integrated Prevention Demonstration Campaign Launched in Western Kenya to Fight HIV, Malaria and Diarrhoeal Disease

... Nicholas Muraguri, the head of Kenya's National aids and STI control program (NASCOP). The ... http://www.vestergaard-frandsen.com National aids and STI control program (NASCOP) of the Ministry ... The program works closely with the National aids Control Council. CHF International is a ...

GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update

... Dr. Robinson is the inventor of GeoVax's HIV-1 aids vaccine technology and co-founder of GeoVax ... announced that its Vaccine was only the 5th aids Vaccine moving forward into Phase 2a human trials ... growth and expansion plans in the aids vaccine arena. Dr. McNally has been a member ...

Thousands Rally in Mexico City and Call for Human Rights Protections in Global AIDS Response

... MEXICO CITY, Aug. 7 /PRNewswire/ -- Thousands of aids activists gathered today for the first-ever ... a key event of the XVII International aids Conference. The activists called on governments ... human rights protections ever at an International aids Conference. Groups representing human rights, ...

Leading AIDS Experts Urge Greater Focus on Behavior-Change Programs to Prevent HIV

... Highly Effective, but Often Overlooked in Global aids Response MEXICO CITY, Aug. 5 /PRNewswire/ -- In ... report released today, an international panel of aids experts calls on global leaders to ... in developing countries seriously affected by aids should work closely with UNAIDS and the World ...

JAMA Commentary Opposes Criminal Punishment for HIV Exposure/Transmission

... Authors to Discuss Issue at International aids Conference, August 3-8 CHICAGO, Aug. 4 ... and Public Health; and internationally recognized aids activist Edwin Cameron, a Justice of the South ... is living with HIV. Michaela Clayton, director of aids and Rights Alliance for South Africa (ARASA) ...

Zounds Hearing Develops and Releases Power BTE Hearing Aid

... Zounds' Digital aids Now Treat 100 Percent of Improvable ... of the Power BTE, Zounds' line of hearing aids is capable of offering a solution for all ... advanced, accessible and affordable hearing aids with exceptional performance." The Z1 Power BTE ...

Pathwork(R) Diagnostics Launches Genomics-Based Test For Hard-To-Identify Tumors Through Its CLIA-Certified Laboratory

... The Pathwork(R) Tissue of Origin Test aids in the Diagnosis of Uncertain ... Diagnostics Laboratory. The new test aids in the diagnosis of tumors of uncertain origin ... through Pathwork Diagnostics Laboratory and aids in determining a tissue's origin so that ...

GeoVax Further Strengthens Management Team

... GOVX), http://www.geovax.com, an Atlanta based aids vaccine development company, is very pleased to ... growth and expansion plans in the aids vaccine arena. "Dr. McNally is joining our team to provide additional expertise to guide our aids vaccine development into advanced Phase 2a human ...

Ardea Biosciences Establishes Scientific Advisory Board for HIV Program

... and Chief Executive Officer of the Aaron Diamond aids Research Center, a world-renowned biomedical ... School. Dr. Ho has been at the forefront of aids research for 27 years, publishing over 350 papers ... the United Kingdom and began working in HIV and aids working mostly at the Chelsea and ...

Genetic Immunity Announces the Appointment of Richard B. Pollard, M.D. as Chief Medical Officer

... twenty years; he cared for his first patient with aids in 1982, and continues to provide primary care ... someone who has spent a quarter century active in aids care, I'm excited to work on the DermaVir Patch ... Dr. Pollard was a pioneer in the field of aids research and today is one of the ...

U.S. Government Awards $15 Million Grant to GeoVax Labs' HIV/AIDS Vaccine Program

... scrutinized and must supply substantial positive aids vaccine data to support their application. IPCAVD ... "This grant will allow GeoVax to move forward our aids vaccine evaluation program more efficiently and ... $15 million in funding will support additional aids vaccine studies as well as expansion of our ...

Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic

... infections that are characteristic of aids as well as the aids virus itself. Data Reported in the ICAAC ... fight infections and certain cancers resulting in aids (Acquired Immune Deficiency Syndrome). ...

Global Experts Explore Entire Spectrum of Aids Vaccine Development

... from 47 countries convene in Seattle for aids Vaccine 2007 Conference ... and specialists convene this week for the aids Vaccine 2007 Conference at the Sheraton Seattle Hotel and Towers. Since the aids Vaccine 2000 Conference in Paris, this event has ...

GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update

... as HIV-1 by vaccinating individuals prior to aids virus infection. The vaccine regimen employs ... boost. Both vaccines deliver over 50% of the aids virus components but can not cause AIDS. ... of GeoVax specific recombinant MVA based aids vaccines. Simultaneously, GeoVax's promising ...

Repair Stem Cell Institute Warns About Real Cost of Embryonic Stem Cell Research

... Why is the FDA, which indiscriminately rushes unproven deadly drugs to aids patients, forbidding six million dying heart patients access to ... therapy?" Is it because heart patients don't count in politics while aids patients do? Or is there another reason why they allow drugs such as ...

FasterCures Rewards Two InnoCentive Solvers for Innovative Ideas to Accelerate Medical Research

... impact. Most recently, InnoCentive worked with the International aids Vaccine Initiative (IAVI) to post a Challenge in this Pavilion seeking new approaches to aids vaccine design. The Challenge , with a $150,000 reward is currently ...

Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals

... Soluble Transferrin Receptor assay and the sTfR/log ferritin index as aids in the diagnosis of iron deficiency anemia and anemia of chronic disease. ... defined in our annual report on Form 10-K. We believe use of this measure aids in the understanding of our operations without the impact of foreign ...

Zounds Offers the Gift of Hearing This Holiday Season With a Range of New Products

... designs, engineers, manufactures, and markets high-performance hearing aids for consumer use with a wide range of hearing impairment from mild to ... a unique customer-friendly testing, fitting and purchase process. Zounds aids are available through a network of branded, state-of-the-art Zounds ...

Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine

... in Europe for the treatment of pneumocystis pneumonia (PCP) in aids patients and for the treatment of Human African trypanosomiasis, also ... Considering the franchise we are building in products to treat cancer and aids patients, pafuramidine, with its attractive activity on resistant strains, ...

ALPCO Introduces a Mouse HMW and Total Adiponectin ELISA

... with ALPCO, states, "Adiponectin is positively associated with insulin sensitivity and this kit is specifically designed for mouse samples so it aids preclinical research. This mouse HMW adiponectin ELISA would be of interest to both academic institutions and biotech companies." Julie Rasku, ...

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

... 13.9 -25% Total 66.9 3% (1) Compared with Q2 2008 3TC - HIV infection and aids Shire receives royalties from GSK on worldwide sales of 3TC(R) sales. Royalties from sales of 3TC for the three months to June 30, 2009 were ...

Viral Genetics Retires Nearly $3.5 Million Convertible Debt and Provides Updates on Capital Structure and Stock Issuances

... on www.pinksheets.com . Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV, aids and other autoimmune diseases using its thymus nuclear protein compound (TNP). The company recently entered into an Exclusive License Agreement with ...

Viral Genetics Information Now Available Through OTCIQ.com and Pink Sheets Website

... About Viral Genetics, Inc.: Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV, aids and other autoimmune diseases using its thymus nuclear protein compound (TNP). The Company recently licensed technology developed by M. Karen Newell, ...